Stockrabit · Analysts
Questions across 26 calls

Saion Mukherjee

Nomura

Anthem Biosciences Limited

Anthem Biosciences Limited CC-Feb26.pdf · 2026-02-05
Thanks for taking my question. On next year, you indicated things should get better. So, should we expect growth closer to what your trajectory has been around 20% in FY27 on back of the existing commercial product and the new launches that you had ramping up?
Great. Just to get some color, because a lot of moving parts here and if I understand correctly, the last few years, you had quite a good ramp-up in some of your commercial products. So, when you look forward for the next couple of years, which will be a bigger growth driver for Anthem? Would it be the ramp -up of your recently commercialized products, like the four that you had, or the ones which are already in the market, you could get more volumes market share? How should we think? You also talked about lateral contracts. So, I am wondering, can those sort of start ramping up pretty quickly? These are like three drivers that I see, if you can give some colors to, which one would be the most, or if you can rate the importance of these drivers for at least in the short term?
Anthem Biosciences Limited CC-Jun25.pdf · 2025-08-14
Yeah, so thanks for taking my question. Sir, I think you mentioned about discussion with the customers on pricing with all this, noise on tariff, et cetera. I'm wondering, two questions here. One is, is there any discussion in the recent past regarding setting up facility in the US? Given that dynamics, do you see that a poss ibility sometime in the future? And then let's say tomorrow there is a tariff imposed, whatever that number is, how will that impact our business? Will we be able to pass on any impact on day 1? How the dynamics would work out in such an eventuality, if you can, take us through that?
Okay. And then the second question would be, you mentioned about new technology frontier and how things are sort of changing at a fast pace. In this backdrop, what would be the potential bottleneck as you try to keep pace? Will it be possible to organically build those capabilities on time or you would require to look at acquisition to sort of, manage this fast changes in technology?

Glenmark Pharmaceuticals Limited

Dr. Lal Path Labs Ltd.

Dr. Lal Path Labs Ltd. CC-Feb26.pdf · 2026-01-30
Good evening. Thanks for taking my question. Sir, you mentioned about the patient volume growth at 4%-5%, which you think can increase going forward. It may not be a step-up, but it can go up. If you can share your thoughts as to what we should look at, what would drive that? And also acquisition, small, big task, is that a possibility you see in the current environment? And can that emerge as a driver for you?
And sir, I mean, are you looking at, how should I say? Like is it like midsized chains, big chains or individual labs? What kind of acquisitions are most likely?

IPCA Laboratories Limited

IPCA Laboratories Limited CC-Jun25.pdf · 2025-08-12
Yes. Thank you for taking my question. So, on Unic hem, we have seen decline in gross margin in this quarter. Also, the overhead expenses for th e consolidated business has gone up, which seem to have impacted the overall EBITDA margin. So, if you can explain the dynamics which is impacting the margin and in the backdrop of this quarter’s results, how are you seeing for the full year? What will be your guidance with respect to consolidated EBITDA margins?
And my second question, on the India business, the re is a 10% growth which is still better than the market, but seem to be a little slower than wha t we had seen in the past. Anything you would like to call out as far as India business and demand environment is concerned?

Fortis Healthcare Limited

Fortis Healthcare Limited CC-Jun25.pdf · 2025-08-07
Yes, this is Saion here from Nomura. Congratulations on a great set of numbers you delivered. Sir, in response to an earlier question, you mentioned about one of the things, which you have worked on in terms of investments and case mix. You mentioned about oncology, which I think is somewhere around mid-teen contribution. Can you also share on robotic surgery, what percentage, either in terms of revenues or number of surgeries that you do? A nd what's the scope for these two ratios to increase over the next, say, 3, 4 years, if you have something in mind in the medium term?
Okay. So your ARPOB growth can sort of be in high single digit, at least for some time, would that be something to look forward to?

Lupin Limited

Lupin Limited CC-Jun25.pdf · 2025-08-06
One question is on this whole tariff scenario. We may see an announcement in the near term. How are you assessing that? Any colour you can provide given the kind of products that you have or other mitigating measures that can be put in place? Basically, broadly trying to understand how you see the impact, let's say, if you have 10% or 15% kind of tariff being put on generic pharmaceuticals?
And the second question is on specialty. You are thinking about it for a while now. Given the changes that we are seeing in the U.S, particularly with respect to the pricing environment, is that changing your thought process around how you should be thinking about going about building the specialty business globally and in the U.S, in particular?

Alkem Laboratories Limited

Alkem Laboratories Limited CC-Dec24.pdf · 2025-02-07
My first question is, I think in the last call, you mentioned that there would be some overhead expenses of around INR70-odd crores. Have those expenses started to come through? Secondly, you guided us toward a 19% EBITDA margin for the full year. In 9 mon ths, it's 21.6%, so it seems like you are on course to sort of beat that number if you can give a revised guidance for fiscal '25?
No. So I'm just wondering -- so you are saying this is for the full year. I mean, in this quarter, is there going to be a step-up in the expenses? I was thinking there would possibly be a step-up.
Alkem Laboratories Limited CC-Sep24.pdf · 2024-11-13
My first question is regarding the full year guidance. I think you talked about 10% growth on top line and I think 18% EBITDA margin. What's your new guidance overall for the company now?
Understood. On the U.S. business, we have seen fairly large volume decline and also you mentioned about price erosion. If you can take us through, is there something you have seen in the recent past, things have deteri orated for the portfolio? And how are you thinking from a slightly longer-term perspective for your U.S. business?
Alkem Laboratories Limited CC-Mar24.pdf · 2024-05-29
Firstly, on your comment on the domestic market, I am wondering the growth of the seasonality is one factor. So, when you think about growth next year at around 10%, given that you have large NLEM portfolio where there is no price increase, are you banking on normalization of seasonal demand to get to this growth?
And sir, how has been the performance of trade generics for you in this fiscal year ? And an associated question is when you talk about volume growth, you see many companies launching their trade generics division and getting aggressive there and you have additional competition from generics private label, etc., So, aren't you worried about these headwinds, which can impact volume growth over the medium-term?

Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Limited CC-Mar24.pdf · 2024-05-07
Hi, thanks for taking the question. I have just one question on R&D. We have seen a significant step up and as you mentioned in your guidance, it looks like you are talking about more than $300 million of R&D spend next year. If you can provide like where this money is being spent, in terms of biosimilars or NCE research and other generics activity?
Ok, thanks. And my second question would be, how do you see the growth in emerging markets in the years ahead, particularly with respect to China and some of the key markets like Brazil, if you can talk about your outlook for fiscal 2025 and 2026?

Gland Pharma Limited

Gland Pharma Limited CC-Sep24.pdf · 2024-11-04
You recently announced the appointment of the CEO Shyamakant Giri. So , can you take us through the thought process of separating your role and that of CEO, and what were the thoughts of hiring someone like Shyamakant Giri to run as a CEO here? And should we read something more strategic here? What are you expecting going forward for the new CEO to sort of focus on?
Yes. Mr. Giri's experience of running frontend especially in ROW emerging market, is that something you are aggressively looking at going forward because you had earlier mentioned about putting up contents?
Gland Pharma Limited CC-Jun24.pdf · 2024-08-06
I just have one question about U.S. business. There seems to be some slowdown or a drop in the U.S. revenues, except Cenexi quarter -on-quarter. So, can you just explain the dynamics there? And how should we think about it in the subsequent quarters?
Okay. Sir, my second question is about your comment on the domestic business, your plans around that, and also acquisitions. If you can throw some light on it , what are you thinking on both these fronts?
Gland Pharma Limited CC-Mar24.pdf · 2024-05-22
Thanks for taking my question. Just wanted to check on Cenexi. So from the current level to breakeven to high teens, what's the timeline and please give some more granular details on the key milestones that you should look out for as far as EBITDA margin improvement is concerned with the timelines please?
How should we think about Cenexi EBITDA for next fiscal and the year after that and I just want to understand what’s the mid- to long-term timeline means here. if you can guide for FY '25 and '26 on the margins?

Cipla Limited

Cipla Limited CC-Sep24.pdf · 2024-10-29
Hi, good evening. My first question was regarding the India business. If you can give some color, particularly on trade generics and consumer, so do you think trade generics has recorded growth this quarter compared to last year given the restructuring we have done? And also on consumer, I remember last year was muted. We had seen like 21% growth this quarter. Why are we seeing sort of that volatility and what's more of sustainable growth here?
Thank you, Ashish. And my second question was on the tender business. So in South Africa, the vaccine tender, so has that scaled up the kind of numbers we are seeing this quarter or this go for it to sort of go up further? And also if you can share like what percentage of your other business, like outside of South Africa International Business, Ex-US, what is the quantity or what is the percentage of tender sales there approximately?